Literature DB >> 2703610

Long-term outcome of patients with hypertrophic cardiomyopathy successfully resuscitated after cardiac arrest.

F Cecchi1, B J Maron, S E Epstein.   

Abstract

This study describes the long-term outcome of 33 patients with hypertrophic cardiomyopathy who experienced a cardiac arrest but were successfully resuscitated. Cardiac arrest occurred at ages 9 to 62 years (mean 32); five patients survived multiple (two or three) arrests. A variety of treatments were administered; 18 patients with left ventricular outflow tract obstruction underwent ventricular septal myotomy-myectomy or mitral valve replacement and also received drug therapy; 15 patients received medical therapy alone. To date, 22 (67%) of the 33 patients have survived after the initial cardiac arrest for periods of 17 months to 22 years (mean 7 years); 12 patients have survived for greater than or equal to 5 and 6 for greater than or equal to 10 years. Of the 22 survivors, 16 have remained asymptomatic or only mildly symptomatic over the period of follow-up; 6 others have become severely symptomatic with heart failure, including 3 with evidence of left ventricular wall thinning and cavity enlargement. Eight patients ultimately died of natural cardiac causes (suddenly or of progressive heart failure) 7 months to 8.4 years (mean 4 years) after their initial cardiac arrest. Actuarial patient survival was 97 +/- 3%, 74 +/- 9% and 61 +/- 11% after 1, 5 and 10 years, respectively. Event-free rate (defined as actuarial survival without recurrent cardiac arrest of death) was 83 +/- 7%, 65 +/- 9% and 53 +/- 11%, respectively. For this group of patients with hypertrophic cardiomyopathy who were treated in a nonsystematic fashion with a variety of therapeutic strategies, the long-term outcome after surviving a cardiac arrest was variable.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1989        PMID: 2703610     DOI: 10.1016/0735-1097(89)90302-1

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  17 in total

Review 1.  Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death.

Authors:  William J McKenna; Elijah R Behr
Journal:  Heart       Date:  2002-02       Impact factor: 5.994

Review 2.  Assessing the risk of sudden cardiac death in a patient with hypertrophic cardiomyopathy.

Authors:  Michael P Frenneaux
Journal:  Heart       Date:  2004-05       Impact factor: 5.994

3.  Malignant familial hypertrophic cardiomyopathy in a family with a 453Arg-->Cys mutation in the beta-myosin heavy chain gene: coexistence of sudden death and end-stage heart failure.

Authors:  Y L Ko; J J Chen; T K Tang; J J Cheng; S Y Lin; Y C Liou; P Kuan; C W Wu; W P Lien; C C Liew
Journal:  Hum Genet       Date:  1996-05       Impact factor: 4.132

Review 4.  Hypertrophic cardiomyopathy in 2013: Current speculations and future perspectives.

Authors:  Georgios K Efthimiadis; Efstathios D Pagourelias; Thomas Gossios; Thomas Zegkos
Journal:  World J Cardiol       Date:  2014-02-26

5.  Prevalence and clinical correlates of QT prolongation in patients with hypertrophic cardiomyopathy.

Authors:  Jonathan N Johnson; Camilla Grifoni; J Martijn Bos; Maha Saber-Ayad; Steve R Ommen; Stefano Nistri; Franco Cecchi; Iacopo Olivotto; Michael J Ackerman
Journal:  Eur Heart J       Date:  2011-02-22       Impact factor: 29.983

6.  Cost-effectiveness of implanted defibrillators in young people with inherited cardiac arrhythmias.

Authors:  Ilan Goldenberg; Arthur J Moss; Barry J Maron; Andrew W Dick; Wojciech Zareba
Journal:  Ann Noninvasive Electrocardiol       Date:  2005-10       Impact factor: 1.468

7.  Risk factors and stratification for sudden cardiac death in patients with hypertrophic cardiomyopathy.

Authors:  B J Maron; F Cecchi; W J McKenna
Journal:  Br Heart J       Date:  1994-12

Review 8.  Management of arrhythmias in hypertrophic cardiomyopathy.

Authors:  J T Stewart; W J McKenna
Journal:  Cardiovasc Drugs Ther       Date:  1994-02       Impact factor: 3.727

9.  Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population.

Authors:  F Cecchi; I Olivotto; A Montereggi; G Squillatini; A Dolara; B J Maron
Journal:  Heart       Date:  1998-04       Impact factor: 5.994

10.  Identification of high risk patients with hypertrophic cardiomyopathy in a northern Greek population.

Authors:  Georgios K Efthimiadis; Christodoulos Pliakos; Efstathios D Pagourelias; Despina G Parcharidou; Georgios Giannakoulas; Vasileios Kamperidis; Stavros Hadjimiltiades; Charalambos Karvounis; Stavros Gavrielidis; Ioannis H Styliadis; Georgios Parcharidis
Journal:  Cardiovasc Ultrasound       Date:  2009-07-26       Impact factor: 2.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.